Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALISADE BIO, INC.PALI · Entity 5803 | Director | July 11, 2024 | July 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALISADE BIO, INC.
Report date July 11, 2024 · Filed July 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.49 · Expires 2034-07-11 | Direct | 2,100 |
Reported balance
After 2024-07-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-07-11 · Grant · Acquired 2,100 · Balance 2,100 F1: Represents partial compensation for services as a director pursuant to Issuer's non-employee director compensation policy, consisting of 2,100 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan. F2: The grants vest fully on the one (1) year anniversary of the grant date. F3: Each option represents the right to purchase one share of common stock at the exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents partial compensation for services as a director pursuant to Issuer's non-employee director compensation policy, consisting of 2,100 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan.
F2: The grants vest fully on the one (1) year anniversary of the grant date.
F3: Each option represents the right to purchase one share of common stock at the exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 11, 2024 Filed Jul 16, 2024 00:13 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock Options · Derivative | 2,100 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001493152-24-027909 · ownership.xml · derivative · entry 1 Fischbein Margery B. · CIK 0001766438 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 2,100 shares Expires 2034-07-11 F1 · security: Represents partial compensation for services as a director pursuant to Issuer's non-employee director compensation policy, consisting of 2,100 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan. F2 · security: The grants vest fully on the one (1) year anniversary of the grant date. F3 · security: Each option represents the right to purchase one share of common stock at the exercise price. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.